All Therapeutics articles – Page 3
-
NewsDr Veit Bergendahl to join Rentschler Biopharma as Chief Operating Officer
New operations lead brings over twenty years of biopharma experience to the CDMO’s Laupheim and Milford sites.
-
NewsFujifilm Biotechnologies inaugurates expanded £400m UK biomanufacturing site
The CDMO’s investment in the North-East based site expansion supports UK production of medicines and vaccines.
-
NewsEMA opens consultation for Annex 15 GMP guidelines
Proposal guideline by EMA anticipated to replace Eudralex Volume 4: Annex 15 Qualification and validation.
-
NewsLilly acquires CAR-T therapy biotech Orna Therapeutics for $2.4bn
Agreement with Orna Therapeutics includes potential best-in-class, immune-targeting in vivo CAR-T therapies.
-
NewsRoche’s fenebrutinib demonstrates decade-first benefit in multiple sclerosis
New phase III data presented at ACRIMS suggests the oral BTK inhibitor could become a first-in-class multiple sclerosis therapy.
-
NewsTitanium dioxide-free drotaverine hydrochloride tablets developed
Study findings indicate an alternative coating that would comply with potential future regulation against use of titanium dioxide as a pharmaceutical excipient.
-
NewsGSK’s Nucala green lit for COPD in expanded EU approval
The EC's decision opens up the monthly biologic for use by COPD patients with an eosinophils phenotype.
-
NewsAstraZeneca’s Imfinzi plus chemotherapy earns CHMP nod in gastric cancer
If approved, the regimen would become the first immunotherapy-based perioperative therapy for adults with early gastric and gastroesophageal cancers in Europe.
-
ArticleTerpenes in medicinal cannabis: a formulation challenge
Dean Hatt, Senior Toxicology Consultant at CRO Broughton, highlights the impact of cannabis compounds in pharmaceutical products.
-
NewsNMD Pharma will ‘accelerate’ rare disease drug ignaseclant despite endpoint miss
But phase II data of the small molecule inhibitor for Charcot-Marie-Tooth disease Types 1 and 2 did show it meeting secondary endpoints for functional improvements.
-
NewsGenentech gains rights to SanegeneBio’s RNAi pipeline for $1.5bn
Licensing agreement with SanegeneBio set to advance potential breakthrough siRNA medicines.
-
NewsUCB wins CHMP favour for first thymidine kinase 2 deficiency treatment
If approved by the European Commission, Kygevvi would provide a new treatment option for eligible patients with the ultra-rare mitochondrial disease in Europe.
-
NewsFDA launches PreCheck pilot programme for US pharma manufacturers
The regulator’s new programme aims to create more efficient regulatory review processes for new pharmaceutical manufacturing facilities.
-
ArticleFrom quantum to clinic: AI reshapes clinical trials
The burden of conducting clinical trials is a significant hurdle in drug discovery. Here, Dr Mark Lambrecht reveals the technological developments that are driving shifts in this space.
-
NewsDr David Berman to join Moderna as Chief Development Officer
Meanwhile, Dr Jacqueline Miller is stepping down as the company's Chief Medical Officer.
-
NewsLilly chooses Pennsylvania for $3.5bn injectables manufacturing facility
Investment in the Lehigh Valley site finalises the last of the pharma company’s four new US manufacturing plants, supporting its onshoring of domestic medicine production.
-
NewsAstraZeneca makes $15bn manufacturing investment in China
Landmark, decade-long investment plan aims to support the pharma company’s 2030 revenue objective of $80 billion.
-
NewsRoche GLP-1 produces “robust” weight loss in late-stage obesity trial
The pharma company’s injectable GLP-1/GIP receptor agonist CT-388 is an important element of its weight loss strategy and also delivered benefits for pre-diabetic patients.
-
NewsFMT shows promise for enhancing immunotherapy effectiveness in advanced cancer
Phase II data derived from the first randomised trial comparing immunotherapy outcomes post-FMT from immunotherapy responders versus placebo.
-
NewsInnovative nanoparticle research could restore antibiotic efficacy
Disrupting drug-resistant Gram-negative pathogens is a potential breakthrough in addressing AMR and enhancing antibiotic success.